tiprankstipranks
Trending News
More News >
Marizyme Incorporated (MRZM)
OTHER OTC:MRZM
US Market

Marizyme (MRZM) Price & Analysis

Compare
5 Followers

MRZM Stock Chart & Stats

$0.05
<$0.01(2.13%)
At close: 4:00 PM EST
$0.05
<$0.01(2.13%)

MRZM FAQ

What was Marizyme Incorporated’s price range in the past 12 months?
Marizyme Incorporated lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
    What is Marizyme Incorporated’s market cap?
    Marizyme Incorporated’s market cap is $132.00.
      When is Marizyme Incorporated’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Marizyme Incorporated’s earnings last quarter?
      Currently, no data Available
      Is Marizyme Incorporated overvalued?
      According to Wall Street analysts Marizyme Incorporated’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Marizyme Incorporated pay dividends?
        Marizyme Incorporated does not currently pay dividends.
        What is Marizyme Incorporated’s EPS estimate?
        Marizyme Incorporated’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Marizyme Incorporated have?
        Marizyme Incorporated has 131,793,090 shares outstanding.
          What happened to Marizyme Incorporated’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Marizyme Incorporated?
          Currently, no hedge funds are holding shares in MRZM
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Marizyme Incorporated

            Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.
            Similar Stocks
            Company
            Price & Change
            Follow
            Biodexa Pharmaceuticals
            Q/C Technologies
            Salarius Pharmaceuticals
            Scinai Immunotherapeutics
            Oragenics
            Popular Stocks